bpc 157 human clinical trial tendon injury randomized Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing Stable Gastric Pentadecapeptide BPC 157

The fatigue lasted four days, not two weeks

doi: 10.1016/ j.celrep.2022.111214 183

W., Fang D

lysosomes remained intact, demonstrating selectivity of organelle targeting In vivo tumour eradication pre-clinical studies have reported tumour eradication in nude mouse xenograft models following PNC-27 treatment Ovarian cancer models intraperitoneal mouse toxicity and maximum tolerated dose studies conducted alongside ex-vivo testing against primary patient-derived epithelial ovarian cancer cultures, demonstrating dose-dependent cytotoxicity including activity against chemotherapy-resistant ovarian cancer lines Haematological malignancy models near-complete cancer cell death reported in leukaemia models, including p53-deficient cells, via HDM-2 membrane binding Cervical cancer models confirmed selective killing of cervical cancer cells with no effect on untransformed cervical cells